Validating a method for the estimate of gait spatio-temporal parameters with IMUs data on healthy and impaired people from two clinical centers

Instrumented gait analysis offers objective clinical outcome assessment. To this purpose, inertial measurement units (IMUs) represent nowadays a very effective solution due to their limited cost, ease of use and improved wearability. The aim of this study was to apply a well-documented IMU-based method to measure gait spatio-temporal parameters in a large number of healthy and gait-impaired subjects, and evaluate its robustness and validity across two clinical centers. Overall, the results of this work represent a robust and reliable foundation for the clinical use of the proposed IMU based method for gait parameters estimation

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

Background: Following the increased survival of patients with metastatic melanoma thanks to immunotherapy and targeted therapy, neoadjuvant approaches are being investigated to address the unmet needs of unresponsive and intolerant patients. We aim to investigate the efficacy of neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma. Methods: The study is a phase II, open-label, randomized non-comparative trial in patients with stage IIIB/C/D surgically resectable, BRAF-mutated and wild-type melanoma, with three possible treatments: (1) vemurafenib 960 mg twice daily from day 1 to 42; (2) vemurafenib 720 mg twice daily from day 1 to 42; (3) cobimetinib 60 mg once daily from day 1 to 21 and from day 29 to 42; and (4) atezolizumab 840 mg for two cycles (day 22 and day 43). Patients will be randomized to three different arms: A) BRAF-mutated patients will receive over 6 weeks (1) + (3); B) BRAF-mutated patients will receive over 6 weeks (2) + (3) + (4); C) BRAF wild-type patients will receive over 6 weeks (3) + (4). All patients will also receive atezolizumab 1200 mg every 3 weeks for 17 cycles after surgery and after a second screening period (up to 6 weeks). Discussion: Neoadjuvant therapy for regional metastases may improve operability and outcomes and facilitate the identification of biomarkers that can guide further lines of treatment. Patients with clinical stage III melanoma may especially benefit from neoadjuvant treatment, as the outcomes of surgery alone are very poor. It is expected that the combination of neoadjuvant and adjuvant treatment may reduce the incidence of relapse and improve survival

The identification of multiple U-turns in gait : comparison of four trunk IMU-based methods

The identification of turns during walking allows for the segmentation into straight and turn walking bouts. Several IMU-based methods were developed to this purpose, however many of them were tested on specific subject population. In this study, we tested four methods for the identification of turns in walking tasks with multiple U-turns that did not exploit any a-priori knowledge of the turn occurrences. We evaluated their robustness by recording IMU data on healthy and pathological subjects (healthy elderly, stroke survivors, patients with Parkinson disease and choreic patients) walking at two different speeds along a closed loop formed by straight bouts and U-turns. Overall, all methods identified correctly the totality of the U-turns when elderly and Parkinsonian patients were analyzed. When stroke survivors and choreic patients were analyzed, U-turns were either missed or erroneously detected in a limited number of cases. The only method using the magnetometer signals was the best performing, highlighting the usefulness of the magnetometer when turns are being investigated

Light electric vehicle enabled by smart systems integration

For the first time in history, the majority of people live now in urban areas. What is more, in the next four decades, the number of people living in the world's urban areas is expected to grow from 3.5 billion to 5.2 billion. At the same time, populations around the world are rapidly ageing. By 2050, the global population of people aged 60 years and over is expected to reach almost 2 billion, with the proportion of older people doubling between 2006 and 2050. This growth and ageing of the population will pose great challenges for urban mobility, which will be addressed within the SilverStream project. In particular, it will develop and demonstrate a radically new light and affordable Light Electric Vehicle concept for the ageing population in congested European cities with scarce parking space